Medicine & Health

Hematologist Amy Zhou, MD, an associate professor at the School of Medicine, values the connections she makes with patients. She is also pursuing research to improve blood cancer treatments.

John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Endowed Professor of Medicine at Washington University School of Medicine in St. Louis, has received the Chancellor’s Award for Innovation and Entrepreneurship for his research contributions.

Researchers at Washington University School of Medicine in St. Louis have found that a strain of gut bacteria can boost immune responses and enhance cancer immunotherapy to fight sarcoma tumors in mice.

A study from biologists and clinicians at Washington University in St. Louis reports that glioblastoma cells have built-in circadian rhythms that create better times of day for treatment.

Researchers at the School of Medicine have received a $5 million grant from the Leukemia & Lymphoma Society to support research aimed at developing new immunotherapies for different types of blood-based cancers.

Sana D. Karam, MD, PhD, a renowned radiation oncologist widely known for cutting-edge cancer research that combines radiation therapy and immunotherapy to treat head and neck, and pancreatic tumors, has been named the James S. McDonnell Professor of Radiation Oncology and head of the Department of Radiation Oncology at the School of Medicine.

Researchers at Washington University School of Medicine have discovered that an FDA-approved epilepsy drug can prevent or slow the growth of NF1-linked optic gliomas in mice, laying the groundwork for a clinical trial.

In a recent study, researchers at Washington University School of Medicine in St. Louis and Whiterabbit.ai showed that artificial intelligence assistance potentially could improve breast-cancer screening by reducing the number of false positives without missing true positives.

A clinical trial led by School of Medicine researchers has shown that a T cell immunotherapy — in which the patients’ own T cells are genetically modified to attack and kill cancer cells — is effective in treating some patients with rare cancers of the body’s soft tissues. The study focused on the rare cancers synovial sarcoma and myxoid round cell liposarcoma.

John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Professor of Medicine at the School of Medicine, delivered the E. Donnall Thomas Lecture in San Antonio at the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.